Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008

200720062004

Sep 22, 2017

Arthur Bedrosian, chief executive officer of Lannett Company, Inc. (NYSE: LCI), has prevailed in his lawsuit with the U.S. Internal Revenue Service (IRS). Bedrosian filed a lawsuit against the...

More
Sep 5, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Esomeprazole...

More
Aug 23, 2017

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "In the coming year, we expect a solid increase in net...

More
Aug 8, 2017
--Company to Report Full Financial Results and Host Conference Call on August 23--

Lannett Company, Inc. (NYSE: LCI) today reported preliminary financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017. "While our industry is currently facing...

More
Aug 1, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 37th Annual Growth Conference on August 9, 2017 at 4 p.m. (ET) at the InterContinental Hotel in

More
Jul 17, 2017

Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Samuel H. Israel as vice president, chief legal officer and general counsel. "I am very pleased to welcome Sam to the Lannett...

More
Jul 14, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Cyproheptadine...

More
Jun 26, 2017
--New Dosage Strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg Represent Lion's Share of the Market and Complement Previously Approved Dosage Strengths--

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 22, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrocodone...

More
Jun 20, 2017

Lannett Company, Inc. (NYSE: LCI) today announced that Patrick G. LePore has been appointed to the company's Board of Directors, effective July 1, 2017. The addition of LePore will increase the...

More
 

print email rss
Lannett Investor Relations
Lannett Company Products